SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
Dr. Mike Gibson and Dr. Tony Urey discuss non-cardiac effects referenced in HELIOS V/HELIOS B, focusing on gastrointestinal adverse events and potential implications for quality of life.
TribeMD
7 min read
December 24, 2025
Carregando conteúdo…
SnackableHealth®
Cardiology
Sources
- Sheikh A et al. Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial. Eur J Heart Fail. 2025 Oct 29. doi: 10.1002/ejhf.70084.
- Sheikh FH et al Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025 May 27;85(20):1943-1955. doi: 10.1016/j.jacc.2025.03.454.
Highlights
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer